Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation
about
Evolution of stimulants to treat ADHD: transdermal methylphenidateFrom Clinical Application to Cognitive Enhancement: The Example of MethylphenidateAttention-deficit/hyperactivity disorder in adults: evidence-based recommendations for managementDevelopment of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primatesPresent and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.Effects of methylphenidate on discounting of delayed rewards in attention deficit/hyperactivity disorder.Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.Effect of methylphenidate on sleep parameters in children with ADHD.Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL/6J mice: potentiation of locomotor activity with oral delivery.Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorderOsmotic, controlled-release methylphenidate for the treatment of ADHD.Osmotic release oral system-methylphenidate improves neural activity during low reward processing in children and adolescents with attention-deficit/hyperactivity disorder.Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.The effects of methylphenidate on cognitive control in active methamphetamine dependence using functional magnetic resonance imaging.OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of ADHD.Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.Studies on bi-layer osmotic pump tablets of water-insoluble allopurinol with large dose: in vitro and in vivo.Role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus?Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.Neuropharmacology of Attention-Deficit/Hyperactivity DisorderImportance of Pharmacokinetic Profile and Timing of Coadministration of Short– and Long–Acting Formulations of Methylphenidate on Patterns of Subjective Responses and Abuse Potential
P2860
Q22252903-CB2E60BC-92BE-499E-94A9-9C53AF4ED15AQ28073785-41EC415C-0FC7-4E76-AE01-F9C8D38E7EA0Q28295525-248BB54A-B660-4D9C-9354-E3A508809FBBQ28393582-943C48CC-6EEC-4819-A5F2-6738DACA1E7BQ33945438-598CB485-742D-452A-A35D-9C7C24171669Q34012703-AC58B397-7B91-4269-8896-717AF7CFE967Q34273853-1A5EBF49-10FB-4A2C-A20A-A5016B5BCC69Q34468658-2CE0E028-AFCE-4ED5-944D-A548CBDD14C0Q34646622-48FCEFBA-45B2-4577-A44D-DDE315D79E09Q35001357-328C6FC3-BC0E-44DB-8904-8DCEB4B3ECB2Q35421270-BB4DDE69-EB5A-4726-BC6C-BACE9F5E00F9Q35833310-07CCBEDC-78AB-4696-BE5B-6D247E1795C2Q35954857-41EB3B8A-5B7E-4897-B687-D8DA1CB2549FQ36613947-A09412BC-6975-4CC0-A718-69D323837F2DQ37184589-E8263EDB-577B-499D-A80F-73521549BDC6Q37354631-736EE12E-F8C6-4CEB-99D2-9C91CBDBBB00Q37620947-454CAA95-CA96-48F2-9596-8856268848FDQ37827879-2B1CFA9C-51EF-4277-9D3F-1E611BD82002Q38101134-A4433C6D-89A0-4E96-BBB9-3157BCD48528Q38859853-D6F5254D-3395-4C8A-AEB0-26906173DCF2Q38953668-21543238-014D-43E2-B719-E46147FD1333Q42612645-85B98F47-29D0-4FA3-9F29-9744793EC938Q46984691-1FBEF1B5-3A79-4651-A8BA-DF97452ED750Q47237324-730412E1-91F3-4F53-A602-57229533A9AAQ50748215-64A47648-BE78-412F-BFE9-98753E14D264Q54574209-0EC6AB80-C1E4-4BF4-A13A-7F0D473C0036Q57277979-F329284B-3B78-41A6-A36E-CF71A9EF3B02Q57399801-BADD25EE-6120-449D-BBDF-C713E99DCEDB
P2860
Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@ast
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@en
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@nl
type
label
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@ast
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@en
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@nl
prefLabel
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@ast
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@en
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@nl
P2860
P1476
Single- and multiple-dose phar ...... thylphenidate HCl) formulation
@en
P2093
B Lindemulder
P2860
P304
P356
10.1177/00912700022009080
P407
P577
2000-04-01T00:00:00Z